Holen Sie sich die Stockscreener-App
15.82
0.13%
-0.02
Handel nachbörslich:
16.02
0.20
+1.26%
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims & Hers Acquires Australian Digital Health Eucalyptus for Up to $1.15B - HIT Consultant
Analysis-Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders - Westlaw Today
Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention - AOL.com
Is Viking Therapeutics Stock Really Going to $125? - AOL.com
Hims & Hers Looks to Expand Globally With Buy of Australian Telehealth Provider - Barron's
Hims & Hers continues global expansion with $1.15B acquisition - TechTarget
Hims & Hers to Acquire Eucalyptus in Deal Valued Up to $1.15B - GuruFocus
Hims & Hers to Acquire Eucalyptus in $1.15 Billion Deal - GuruFocus
Hims & Hers Health, Inc. (HIMS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
M&A News: Hims & Hers (HIMS) Expands Globally with $1.15B Eucalyptus Buyout ahead of Q4 Earnings - TipRanks
Can Platform Strength Support Hims & Hers Stock Before Q4 Earnings? - TradingView
Hims & Hers Health Stock Resumes Climb on Acquisition News - Schaeffer's Investment Research
Hims & Hers Health (HIMS) Rises on Eucalyptus Acquisition - GuruFocus
Hims plans to acquire Eucalyptus for up to $1.15B - Axios
Hims & Hers (HIMS) Stock: Company Acquires Eucalyptus for Up to $1.15 Billion - Blockonomi
What Is HIMS Worth Without GLP-1? Earnings Preview (NYSE:HIMS) - Seeking Alpha
4 stocks to watch on Thursday: HIMS, DPZ, WMT, PSX - Seeking Alpha
Why Is Hims & Hers Health Stock Trading Higher Today?Hims & Hers Health (NYSE:HIMS) - Benzinga
Hims & Hers under fire over copycat weight loss drugs - AOL.com
Hims & Hers to acquire Eucalyptus for up to $1.15 billion - Investing.com
Hims & Hers Health (HIMS) to Acquire Eucalyptus in $1.15 Billion Deal - GuruFocus
Hims & Hers is spending more than $1 billion in a push to expand globally - MarketWatch
Hims & Hers to acquire Australian digital health firm Eucalyptus, expanding international footprint - Proactive financial news
US FDA says Novo's obesity pill TV Ad is false or misleading - AOL.com
US Premarket Movers: Carvana, Deere, Hims & Hers, Walmart - Bloomberg.com
Forget Ozempic: This Obesity‑Drug Giant Is Grabbing the Biggest Slice of the GLP‑1 Gold Rush - AOL.com
Hims & Hers Health to acquire Australia’s Eucalyptus for up to $1.15 billion - 1470 & 100.3 WMBD
Hims & Hers Stock Jumps on $1.15 Billion Deal to Acquire Australian Telehealth Provider - Barron's
Hims & Hers to Acquire Eucalyptus in Global Expansion - TipRanks
Hims & Hers Jumps Premarket After $1.15B Global Expansion Deal - Tokenist
Why Hims & Hers Stock Is Sliding Today - TipRanks
Hims & Hers stock rises after agreement to acquire Eucalyptus By Investing.com - Investing.com Australia
Hims & Hers stock rises after agreement to acquire Eucalyptus - Investing.com UK
Hims & Hers to buy Australian digital health firm Eucalyptus for over $1B - Seeking Alpha
HIMS Acquires Eucalyptus in Deal Worth Up to $1.15 Billion - GuruFocus
Hims & Hers (HIMS) Plans Major Expansion with Eucalyptus Acquisi - GuruFocus
Hims & Hers Health Makes Australia, Japan Foray With $1.15 Billion Eucalyptus Acquisition - Stocktwits
Hims & Hers to Acquire Eucalyptus in Deal Valued Up to $1.15 Billion - TradingView
Hims & Hers Health to acquire Australia's Eucalyptus for up to $1.15 billion - Reuters
Hims & Hers Health to Acquire Australia's Eucalyptus for up to $1.15 Billion - U.S. News & World Report
Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders - Reuters
Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform - The Joplin Globe
How We’re Becoming the Leading Global Consumer Health Platform - Hims & Hers Newsroom
Hims & Hers Health, Inc. (HIMS) Stock Dips While Market Gains: Key Facts - Yahoo Finance Singapore
Is Hims & Hers Health Inc Gaining or Losing Market Support? - Benzinga
HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law Firm - GlobeNewswire
Hims And Hers Weighs Legal Risks Against Growth In Longevity Pivot - Yahoo Finance
Hims stock hits 52-week low at 15.62 USD - Investing.com India
Hims & Hers Health: 5 Key Questions Ahead Of Critical Q4 Earnings (NYSE:HIMS) - Seeking Alpha
Do You Think Hims & Hers Health (HIMS) is Positioned for Long-Term Growth? - Insider Monkey
Why the FDA is cracking down on compound GLP-1 drugs for weight loss - Scientific American
Pre-Market: HIMS (Hims & Hers NYSE) $16.27 on 18 Feb 2026: earnings in focus - Meyka
Deutsche Bank Cite Near-Term Growth Concerns For Hims & Hers Health, Inc. (HIMS) Following GLP-1 Launch Reversal - Finviz
How Ozempic Brought a Napster Moment to Big Pharma - The Wall Street Journal
Market Whales and Their Recent Bets on HIMS Options - Benzinga
Novo Nordisk Patent Fight With Hims And Hers Puts Valuation In Focus - Yahoo Finance
Wall Street Sees 84% Upside in Hims & Hers (HIMS) Despite This Month’s 48% Selloff - 24/7 Wall St.
Analysts Estimate Hims & Hers Health, Inc. (HIMS) to Report a Decline in Earnings: What to Look Out for - Finviz
Hims & Hers Health Stock (HIMS) Opinions on Earnings Beat - Quiver Quantitative
Short Sellers Target Hims & Hers Amid Regulatory and Legal Challenges - AD HOC NEWS
Hims & Hers Health (HIMS) to Release Earnings on Monday - MarketBeat
0.49%
1.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):